newli
emerg
reemerg
viral
threat
continu
challeng
medic
public
health
system
incur
econom
cost
individu
countri
influenza
viru
main
caus
threat
respons
million
sever
case
death
scenario
even
wors
pandem
year
virul
influenza
spanish
flu
infect
approxim
world
popul
kill
case
fatal
rate
asian
influenza
hong
kong
influenza
pandem
influenza
report
lower
estim
rate
alarmingli
sever
unpreced
epizoot
avian
influenza
virus
eg
cross
speci
barrier
caus
human
death
pose
increas
threat
humantohuman
infect
human
accompani
aggress
proinflammatori
respons
insuffici
control
antiinflammatori
respons
combin
event
call
cytokin
storm
event
influenza
infect
sever
diseas
result
interplay
viral
virul
host
resist
mild
infect
host
limit
moder
resist
disrupt
homeostasi
restor
rapidli
howev
infect
caus
influenza
viru
resist
becam
hyperact
result
excess
inflammatori
reaction
known
cytokin
storm
sever
experiment
studi
clinic
trial
suggest
cytokin
storm
correl
directli
tissu
injuri
unfavor
prognosi
sever
howev
understand
mechan
promot
cytokin
storm
remain
limit
review
focu
potenti
mechan
respons
sever
influenzainduc
cytokin
storm
therapeut
strategi
might
use
improv
clinic
prognosi
infect
respiratori
epitheli
cell
primari
target
influenza
viru
also
choreograph
cytokin
amplif
follow
primari
exposur
progeni
virus
prolifer
within
cell
infect
cell
includ
alveolar
inflammatori
respons
trigger
infect
cell
die
apoptosi
initi
respons
organ
harm
stimuli
acut
inflamm
character
increas
blood
flow
enabl
plasma
leukocyt
reach
extravascular
site
injuri
elev
local
temperatur
caus
acut
inflammatori
respons
also
mark
activ
proinflammatori
cytokin
proinflammatori
cytokin
chemokin
lead
recruit
inflammatori
increas
express
inflammatori
antivir
apoptot
gene
occur
accompani
abund
immun
cell
infiltr
tissu
figur
time
regen
process
resolut
damag
initi
case
function
complet
restor
repar
howev
sever
inflamm
associ
cytokin
storm
seriou
patholog
chang
observ
diffus
alveolar
damag
hyalin
membran
format
fibrin
exud
fibrot
sign
sever
capillari
damag
immunopatholog
injuri
persist
organ
moreov
sever
inflammatori
cytokineschemokin
spill
circul
result
system
cytokin
storm
respons
multiorgan
inflammatori
respons
begin
pathogenassoci
molecular
pattern
pamp
viru
recogn
pattern
recognit
receptor
prr
innat
immun
specif
proinflammatori
cytokin
express
downstream
signal
cascad
prr
trigger
research
great
interest
explor
associ
polymorph
prr
host
suscept
cytokin
storm
may
help
explain
individu
other
seem
rel
resist
cytokin
sever
cytokin
storm
markedli
higher
level
proinflammatori
cytokin
includ
interferon
ifn
tumor
necrosi
factor
tnf
interleukin
il
chemokin
detect
patient
hospit
sever
influenza
sever
cytokin
storm
rare
observ
season
mild
indic
high
cytokinechemokin
level
correl
strongli
diseas
sever
interferon
famili
critic
role
innat
immun
respons
number
protein
antivir
immunomodulatori
properti
produc
ifn
signal
pathway
although
overproduct
ifn
earli
stage
infect
like
lead
irrevers
lung
damag
mice
ifn
signal
pathway
may
also
import
restrict
dissemin
key
cytokin
cytokin
storm
like
account
escal
howev
tnf
mice
mice
treat
antitnfantibodi
chang
surviv
compar
control
follow
challeng
main
proinflammatori
cytokin
releas
host
viral
infect
express
earli
stage
infect
follow
increas
express
receptor
signal
respons
acut
immunopatholog
tissu
mice
shown
wors
outcom
infect
suggest
pathway
unlik
proinflammatori
cytokin
chemokin
often
specif
chemotact
activ
enabl
monocyt
tlymphocyt
migrat
blood
vessel
site
exampl
monocyt
chemoattract
protein
mcp
major
chemotact
factor
neutrophil
monocyt
respect
note
level
interferoninduc
protein
ip
macrophag
inflammatori
protein
mip
monokin
induc
mig
abnorm
elev
fatal
case
influenza
infect
highest
level
among
mice
exhibit
ineffici
viral
clearanc
reduc
mortal
lung
sever
also
investig
role
sever
chemokin
receptor
receptor
primari
receptor
sever
influenza
infect
interestingli
mice
display
excess
inflammatori
respons
increas
mortal
mice
display
decreas
inflammatori
respons
mortal
develop
significantli
elev
viral
evid
partli
suggest
patholog
sever
influenza
mediat
cytokin
respons
viral
load
gener
cytokin
respons
induc
directli
influenza
viru
sprawl
network
amplifi
autocrin
paracrin
mediat
cascad
pathway
associ
prr
il
ifn
tnf
cyclooxygenas
cox
cjun
ntermin
kinas
jnk
activ
induc
transcript
nfkb
format
cytokinechemokinedriven
feedforward
inflammatori
circuit
may
respons
escal
cytokin
howev
key
factor
network
especi
specif
pathogenesi
sever
influenza
still
unknown
use
networkbas
system
biolog
approach
jin
et
made
success
attempt
elucid
network
properti
sever
influenza
studi
demonstr
nuclear
factorkappa
b
obviou
differ
normal
inflammatori
complic
aris
sever
influenza
associ
inflammatori
cell
monocytesmacrophag
main
cell
recruit
alveolar
space
initi
respons
viral
increas
cytokin
product
chemoattract
addit
immun
cell
lesion
nevertheless
also
suscept
influenza
viral
infect
deplet
monocytesmacrophag
prevent
immunopatholog
indic
import
role
viral
cell
respons
immunopatholog
viral
clearanc
infect
lethal
lung
injuri
trigger
transfer
antigenspecif
cell
transgen
mice
express
influenza
ha
antigen
howev
lethal
lung
injuri
trigger
mice
defect
epitheli
earli
growth
suggest
critic
regul
immunopatholog
cell
includ
treg
identifi
contribut
immunopatholog
viral
clearanc
influenza
infect
sever
respiratori
diseas
influenza
often
character
earli
secret
treg
regulatori
cell
key
manag
control
degre
cellular
immun
respons
viral
infect
particularli
prolifer
memori
cell
effect
control
memori
treg
agspecif
manner
mhc
class
ii
corticosteroid
class
steroid
hormon
exhibit
antiinflammatori
activ
via
bind
cytoplasm
corticosteroid
receptor
regul
transcript
antiinflammatori
thu
corticosteroid
wide
use
antiinflammatori
treatment
influenza
pandem
nearli
patient
franc
treat
acut
respiratori
distress
syndrom
ard
use
adjuv
system
avian
influenza
outbreak
china
patient
receiv
system
corticosteroid
howev
evid
support
use
corticosteroid
sever
influenza
inconclus
experiment
studi
shown
mice
infect
influenza
similar
mortal
corticosteroidtr
group
control
clinic
trial
even
identifi
system
corticosteroid
respons
increas
longterm
contrast
anoth
independ
research
studi
report
system
use
corticosteroid
allevi
pandem
influenzaassoci
pneumonia
without
advers
thu
use
corticosteroid
sever
influenza
controversi
still
need
observ
peroxisom
proliferatoractiv
receptor
ppar
includ
critic
regul
inflamm
agonist
gemfibrozil
propos
treat
sever
influenza
due
abil
inhibit
tnf
howev
anoth
research
report
gemfibrozil
administ
postinfect
effect
mortal
avian
influenzainfect
mice
suggest
pharmacolog
mechan
gemfibrozil
treat
sever
influenza
still
need
character
littl
research
use
agonist
treat
sever
influenza
perhap
focus
trophic
effect
oligodendrocyt
vitro
bezafibr
shown
partial
protect
patient
influenzaassoci
howev
agonist
eg
rosiglitazon
pioglitazon
consid
promis
candid
improv
clinic
outcom
sever
thiazolidinedion
downregul
inflammatori
respons
viral
pneumonia
also
increas
surviv
influenzainfect
moreov
benefit
agonist
treatment
found
higher
addit
natur
agonist
biochanin
extract
red
clover
confirm
similar
immunomodulatori
effect
gemfibrozil
treatment
influenza
recent
year
increas
interest
develop
novel
agent
antiimmunopatholog
injuri
activ
receptor
five
specif
receptor
found
regul
downstream
signal
pathway
howev
locat
mainli
pulmonari
endotheli
cell
exhibit
cytokinestormblunt
activ
suppress
innat
cellular
cytokinechemokin
exampl
report
protect
mice
lethal
infect
sever
influenza
blunt
cytokin
innat
immun
cell
particularli
murin
model
infect
pandem
influenza
receptor
agonist
alon
reduc
death
lethal
infect
compar
protect
offer
antivir
neuraminidas
inhibitor
furthermor
combin
therapi
two
agent
achiev
optim
protect
far
promis
result
improv
outcom
sever
influenza
use
immunomodulatori
strategi
select
cox
inhibitor
celecoxib
mesalazin
wide
use
clinic
antipyret
analges
antiinflammatori
properti
monotherapi
celecoxib
murin
model
influenza
consider
modul
diseas
howev
use
inhibitor
combin
neuraminidas
inhibitor
shown
improv
surviv
mice
infect
tripl
combin
therapi
zalamivir
celecoxib
mesalazin
significantli
reduc
mortal
level
cytokineschemokin
infect
data
demonstr
inhibitor
may
provid
addit
benefit
combin
antivir
reactiv
oxygen
speci
ro
play
central
role
inflammatori
respons
viral
replic
antioxid
exert
antivir
antiinflammatori
effect
may
also
effect
treatment
cytokin
storm
induc
sever
nacetylcystein
nac
modifi
form
amino
acid
cystein
shown
inhibit
replic
product
proinflammatori
molecul
eg
lung
epitheli
glycyrrhizin
inhibitor
hydroxysteroid
dehydrogenas
shown
inhibit
replic
proinflammatori
gene
interestingli
investig
show
vitamin
c
benefici
patient
suffer
sever
avian
fact
mani
plantderiv
antioxid
eg
polyphenol
flavonoid
etc
could
also
reduc
damag
epitheli
cell
mortal
mice
caus
lethal
howev
current
evid
indic
monotherapi
use
antioxid
limit
effect
cytokin
storm
combin
antivir
would
still
although
still
fulli
understand
complex
natur
cytokin
storm
tnf
consid
key
cytokin
acut
viral
diseas
eg
influenza
viru
dengu
viru
ebola
viru
inde
experiment
studi
shown
tnf
affect
balanc
local
microenviron
also
exert
broad
system
effect
enter
thu
antitnf
strategi
may
reason
way
treat
sever
influenza
studi
report
treatment
use
tnfneutral
monoclon
antibodi
solubl
tnf
receptor
fusion
protein
reduc
cytokin
product
inflammatori
cell
infiltr
influenzainfect
murin
howev
improv
surviv
rate
observ
thu
evid
clinic
use
antitnf
therapi
sever
influenza
current
inconsist
clinic
trial
evalu
efficaci
antitnf
strategi
still
need
intraven
immunoglobulin
ivig
therapi
use
concentr
globulin
prepar
pool
human
plasma
treatment
acut
infect
mechan
ivig
suppress
harm
inflamm
definit
identifi
believ
involv
multipl
immunomodulatori
effect
block
fc
receptor
associ
toler
self
sever
inflammatori
strategi
use
treatment
viralinduc
cytokin
storm
confirm
improv
outcom
infect
sar
pandem
metaanalysi
suggest
earli
administr
blood
product
could
reduc
anywher
patient
death
pneumonia
influenza
evid
benefici
effect
ivig
therapi
obtain
influenza
infect
multivari
analysi
patient
receiv
either
hyperimmun
normal
ivig
within
five
day
symptom
onset
found
hyperimmun
ivig
treatment
independ
respons
reduc
mortal
result
suggest
passiv
immunotherapi
hyperimmun
globulin
potenti
strategi
treatment
sever
influenza
inexpens
gener
statin
angiotensin
receptor
blocker
arb
angiotensinconvert
enzym
inhibitor
acei
also
propos
potenti
immunomodulatori
agent
reduc
inflamm
caus
influenza
statin
competit
inhibitor
enzym
coenzym
hmgcoa
reductas
exert
multipl
immunomodulatori
effect
modul
activ
immun
effector
cell
via
inhibit
ro
ii
antagon
high
mobil
group
box
protein
inhibit
proinflammatori
cytokin
express
iii
suppress
gene
murin
model
infect
influenza
viru
combin
statin
caffein
allevi
lung
injuri
inhibit
viral
replic
appear
similar
efficaci
oseltamivir
howev
independ
research
studi
show
statin
prevent
patient
infect
pandem
influenza
develop
sever
direct
evid
shown
acei
arb
might
effect
therapi
sever
influenzainduc
cytokin
storm
howev
agent
inhibit
inflammatori
respons
induc
angiotensin
ii
improv
surviv
mice
sever
experiment
model
acut
lung
furthermor
clinic
trial
also
confirm
agent
reduc
risk
pneumonia
pneumoniarel
thu
pharmacodynam
effect
mechan
gener
deserv
research
sever
immunomodulatori
agent
assess
efficaci
vitro
vivo
lin
confirm
ccr
inhibitortr
mice
signific
increas
surviv
versu
placebo
infect
influenza
adenosin
protein
kinas
ampk
enzym
exert
antiinflammatori
effect
activ
ampk
activ
aminoimidazol
carboxamid
ribonucleotid
aicar
report
increas
surviv
influenzainfect
mice
combin
pioglitazon
improv
surviv
could
impart
surviv
signal
cell
upregul
antiapoptosi
gene
express
play
critic
role
tcellmedi
immunopatholog
lung
viral
fusion
protein
treatment
shown
block
interact
ligand
antigenpres
cell
elimin
weight
loss
cachexia
without
prevent
viral
clearanc
influenzainfect
murin
note
inhibitor
interferon
signal
suppressor
cytokin
signal
socss
shown
neg
regulatori
properti
particip
neg
feedback
loop
jak
epiderm
growth
factor
receptor
tyrosin
kinas
protein
also
potenti
agent
protect
cytokin
storm
sever
find
offer
great
deal
encourag
treat
influenzainduc
cytokin
storm
immunomodulatori
agent
antibiot
antivir
also
known
possess
antiinflammatori
effect
immunomodulatori
properti
addit
antipathogen
action
vitro
vivo
studi
provid
ampl
evid
immunomodulatori
antiinflammatori
activ
macrolid
eg
erythromycin
clarithromycin
roxithromycin
azithromycin
macrolid
interfer
replic
cycl
influenza
viru
result
inhibit
viral
product
infect
cell
moreov
macrolid
treatment
influenza
virusinfect
mice
increas
surviv
suppress
inflamm
reduc
inflammatori
cell
arbidol
antivir
complic
mechan
membranefusioninhibit
immunomodulatori
activ
may
contribut
current
research
confirm
posttreat
arbidolreduc
mortal
lung
lesion
format
viralinduc
inflamm
modul
express
proinflammatori
cytokin
influenzainfect
data
suggest
arbidol
might
also
effect
treatment
sever
influenza
infect
human
herb
may
also
potenti
choic
patient
hospit
sever
influenza
sever
chines
herbal
prescript
recommend
author
chines
govern
systemat
review
clinic
trial
herb
use
influenza
treatment
reveal
herbal
medicin
show
posit
effect
viral
shed
posit
effect
resolut
relief
moreov
mani
herb
exhibit
benefici
immunomodulatori
effect
rapid
recoveri
viral
infect
might
effect
treatment
infect
sever
report
extract
jiaweiyupingfengtang
tradit
chines
herbal
formula
allevi
influenzainduc
lung
lesion
antivir
immunomodulatori
also
confirm
epigallocatechin
gallat
egcg
green
teaderiv
polyphenol
inhibit
pathogenesi
influenzainfect
cell
due
antioxid
polyphenol
triterpenoid
flavonoid
herb
may
potenti
activ
compon
protect
cytokin
storm
sever
influenza
unpublish
data
howev
confirm
larger
seri
clinic
studi
requir
persist
outbreak
avian
influenza
asia
part
africa
suggest
sever
influenza
avian
influenza
pose
major
threat
public
health
mani
severeinfluenzainfect
patient
die
overwhelm
viral
pneumonia
seriou
complic
caus
cytokin
storm
review
highlight
patholog
cytokin
storm
particular
enhanc
broad
immun
respons
sometim
worsen
outcom
diseas
although
precis
molecular
event
surround
cytokin
storm
clarifi
immunomodulatori
strategi
novel
approach
target
host
respons
sever
influenza
advoc
consid
agent
work
differ
intracellular
pathway
might
ideal
use
combin
obtain
better
outcom
base
promis
result
mention
combin
therapi
pair
ppar
agonist
inhibitor
antioxid
convent
antivir
agent
promis
treatment
deserv
studi
random
clinic
trial
approach
especi
therapeut
strategi
target
signal
pathway
either
suppress
redund
immun
respons
reduc
viral
replic
particularli
noteworthi
